GleamWall
中文EN

CABA Cabaletta Bio, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1759138 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-19.5%
TTM EPS YoY44.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-89.5%
ROA-72.0%
ROIC (approx.)-479.6%
Asset turnover—

Leverage & solvency

Liabilities / assets15.6%
Debt / equity0.00x
Current ratio6.55x
Interest coverage-87.26x

Cash quality & payout

Operating cash flow / net income0.86x
Accruals ratio-10.4%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$142.67M$97.20M
SG&A expense$29.57M$27.94M
Operating income-$172.24M-$125.14M
Interest expense$2.00M$748,000
Income tax$0$0
Net income-$167.86M-$115.86M
EBITDA-$170.59M-$123.43M
EPS (basic)-2.10-2.34
EPS (diluted)-2.10-2.34
Balance sheet
Cash & equivalents$82.98M$163.96M
Short-term investments$50.62M$0
Current assets$138.87M$166.68M
PP&E, net$1.92M$2.74M
Total assets$165.08M$185.05M
Current liabilities$50.15M$27.09M
Total liabilities$53.03M$32.71M
Shareholders' equity$112.05M$152.34M
Shares outstanding100.48M50.74M
Cash flow statement
Operating cash flow-$131.08M-$88.22M
Capital expenditure$1.23M$2.21M
Free cash flow-$132.31M-$90.43M
Investing cash flow-$50.27M$47.29M
Financing cash flow$100.35M$11.68M
Depreciation & amortization$1.65M$1.71M
Stock-based compensation$20.94M$19.46M

Free plan shows the latest 2 periods; Pro shows all 8 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.